Four drugs in this group are FDA-approved for weight management. The rest are approved for something else, or research-only.
The two most prescribed are semaglutide and tirzepatide. Their price depends on who fills them.
The approved four, and what the labels cover
Wegovy is semaglutide, approved for chronic weight management in adults [1].
The label sets a starting BMI of 30 or more. Or 27 or more with a weight-related condition [1].
Zepbound is tirzepatide. FDA approved it on November 8, 2023, for the same use [2].
Its approval letter uses the same BMI thresholds. It is an adjunct to diet and activity [2].
Saxenda is liraglutide, a daily injection. FDA approved it on December 23, 2014, for chronic weight management [10].
Foundayo is orforglipron, a daily tablet. FDA approved it on April 1, 2026, for the same use [11].
What the trials behind them found
STEP 1 enrolled 1,961 adults without diabetes [3]. They took semaglutide 2.4 mg weekly or placebo.
At week 68, mean weight change was -14.9% on semaglutide and -2.4% on placebo [3].
SURMOUNT-1 enrolled 2,539 adults without diabetes for 72 weeks [4]. It tested three weekly tirzepatide doses.
At 15 mg, mean weight change was -20.9%. On placebo it was -3.1% [4].
Both trials added a lifestyle program. Both figures hold only for those doses and that duration.
What a month costs
| Peptide | Sellers | Low | Typical | High |
|---|---|---|---|---|
| Semaglutide | 386 | $76 | $189 | $485 |
| Tirzepatide | 370 | $83 | $249 | $634 |
| Liraglutide | 4 | $160 | $295 | $516 |
| Orforglipron | 7 | $149 | $233 | $298 |
Most of those prices are for compounded versions. Sellers set their own plans, so the spread is wide.
Every figure is a published monthly price. Consult fees and membership charges can sit outside it.
Ask what dose the price assumes. Doses step up over the first months on both labels.
The rest of the list
| Peptide | Status on this site |
|---|---|
| Semaglutide | FDA-approved |
| Tirzepatide | FDA-approved |
| Liraglutide | FDA-approved |
| Orforglipron | FDA-approved |
| Tesamorelin | Approved as a brand only, not for weight loss |
| MOTS-c | Research only: on no compounding list |
| BPC-157 | Research only: on no compounding list |
MOTS-c is on no FDA compounding list [6]. Its nominators proposed it for obesity, among other uses.
FDA's July 2026 briefing found no clinical studies of those uses [7]. It proposed not adding MOTS-c.
FDA's advisory committee disagreed. It voted to recommend adding MOTS-c [8]. The vote was 7 to 5, with two abstentions [9]. The vote is not binding [8]. Pharmacies may not compound it until final rulemaking [8].
BPC-157 is in the same position. See why you can't get a BPC-157 prescription.
Tesamorelin is approved only as the brand Egrifta, for belly fat in adults with HIV. Its label says it is not for weight loss.
Compounded tesamorelin has no lawful route, so it gets no price here. The tesamorelin cost guide explains why.
Peptides sold online as research chemicals are a separate market. See what research use only means.
Getting one prescribed
Every approved one needs a prescription. Most cash-pay sellers run it through a telehealth visit.
The steps and their costs are in how online peptide therapy works. Which peptides are legal to prescribe at all is in are peptides legal.
Every price board is on the prices page.